ClinicalTrials.gg
WithdrawnNCT06970405Updated Sep 17, 2025

Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women

A Phase 1 interventional study of Garetosmab and Matching Placebo in Obesity, sponsored by Regeneron Pharmaceuticals. Withdrawn. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on otherwise healthy participants with obesity.

The aim of the study is to see how safe and tolerable the study drug is.

The study is looking at several other research questions, including:

  • How much study drug is in the blood at different times
  • What effect the study drug has on the blood clotting
  • What effect the study drug has on hormone levels
  • What effect the study drug has on some organs that produce hormones
  • What effect hormones have on the side effects produced by the study drug
  • Whether the body makes antibodies against the study drug (which could change how well the drug works or could lead to side effects)
02

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Healthy
  • Postmenopausal
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participants with obesity (defined as (BMI) ≥30 kg/m2) who are otherwise healthy, as defined in the protocol
  2. Women must be , as defined in the protocol
  3. Serum testosterone within age-adjusted normal range for men at screening
  4. The count is within the normal lower and upper laboratory range

Key Exclusion Criteria:

  1. Patients diagnosed with Type 1 or Type 2 diabetes, as defined in the protocol
  2. History of any severe, non-traumatic bleeding, and or a known pre-existing medical history of a bleeding, as defined in the protocol
  3. History of cardiovascular (eg, uncontrolled blood pressure), endocrine, respiratory, hepatic, renal, gastrointestinal, hematological, psychiatric, or neurological disease, as defined in the protocol
  4. Any in the last 5 years prior to screening visit, except for non-melanoma skin cancer that have been resected with no evidence of disease
  5. Any chronic active infection or has received anti- Virus (HCV) treatments within the previous 6 months, as defined in the protocol
  6. Antiplatelet therapy (eg clopidogrel, aspirin), anticoagulants (eg, warfarin, heparin, factor Xa inhibitor, or thrombin inhibitors) in the last 90 days or within 5 half-lives of the therapy at screening, whichever is longer
  7. Use in the previous 90 days for >7 consecutive days at screening of anti-obesity medications, anabolic agents, systemic , androgens, estrogens, or progestogens. Chronic stable doses of thyroid hormones in participants with normal thyroid function are allowed
  8. For women, current use, or past use in the last 90 days at screening of hormonal replacement or therapy

NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    High Dose

    Randomized per the protocol

    Drug: Garetosmab

  • Experimental
    Low Dose

    Randomized per the protocol

    Drug: Garetosmab

  • Placebo comparator
    Placebo

    Randomized per the protocol

    Drug: Matching Placebo

Interventions

  • Administered per the protocol

    Also known as: REGN2477

  • DrugMatching Placebo

    Administered per the protocol

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Through Week 32

  2. Severity of TEAEs

    Time frame: Through Week 32

Secondary outcomes

  1. Change in serum Follicle Stimulating Hormone (FSH) level in response to gonadotropin-releasing hormone (GnRH) injection

    Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH

  2. Percent change in serum FSH level in response to GnRH injection

    Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH

  3. Change in serum Luteinizing Hormone (LH) level in response to GnRH injection

    Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH

  4. Percent change in serum LH level in response to GnRH injection

    Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH

  5. Change in serum total testosterone level in response to GnRH injection

    Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH

  6. Percent change in serum total testosterone level in response to GnRH injection

    Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH

  7. Change in serum free testosterone level in response to GnRH injection

    Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH

  8. Percent change in serum free testosterone level in response to GnRH injection

    Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH

  9. Change in serum estradiol level in response to GnRH injection

    Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH

  10. Percent change in serum estradiol level in response to GnRH injection

    Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH

  11. Change in serum 17-hydroxyprogesterone (17-OHP) level in response to GnRH injection

    Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH

  12. Percent change in serum 17-OHP level in response to GnRH injection

    Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH

  13. Change in serum Dehydroepiandrosterone Sulphate (DHEA-S) level in response to GnRH injection

    Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH

  14. Percent change in serum DHEA-S level in response to GnRH injection

    Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH

  15. Change in serum androstenedione level in response to GnRH injection

    Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH

  16. Percent change in serum androstenedione level in response to GnRH injection

    Time frame: Pre-GnRH Baseline, Through Week 20 Post-GnRH

  17. Change in cortisol level in response to Adrenocorticotropic Hormone (ACTH) level injection

    Time frame: Pre-ACTH Baseline, Through Week 20 post-ACTH

  18. Percent change in cortisol level in response to ACTH injection

    Time frame: Pre-ACTH Baseline, Through Week 20 post-ACTH

  19. Concentrations of garetosmab in serum

    Time frame: Through Week 32

  20. Concentrations of total activin A in serum

    Time frame: Through Week 32

  21. Change in bleeding time

    Time frame: Baseline, At Week 8

  22. Percent change in bleeding time

    Time frame: Baseline, At Week 8

  23. Change in thrombin time

    Time frame: Baseline, At Week 8

  24. Percent change in thrombin time

    Time frame: Baseline, At Week 8

  25. Change in Activated Partial Thromboplastin Time (aPTT)

    Time frame: Baseline, At Week 8

  26. Percent change in aPTT

    Time frame: Baseline, At Week 8

  27. Change in Prothrombin Time (PT)

    Time frame: Baseline, At Week 8

  28. Percent change in PT

    Time frame: Baseline, At Week 8

  29. Change in International Normalized Ratio (INR)

    Time frame: Baseline, At Week 8

  30. Percent change in INR

    Time frame: Baseline, At Week 8

  31. Change in platelets count

    Time frame: Baseline, At Week 8

  32. Percent change in platelets count

    Time frame: Baseline, At Week 8

  33. Change in serum ACTH level

    Time frame: Baseline, Through Week 20

  34. Percent change in serum ACTH level

    Time frame: Baseline, Through Week 20

  35. Change in serum FSH level

    Time frame: Baseline, Through Week 20

  36. Percent change in serum FSH level

    Time frame: Baseline, Through Week 20

  37. Change in serum LH level

    Time frame: Baseline, Through Week 20

  38. Percent change in serum LH level

    Time frame: Baseline, Through Week 20

  39. Change in serum Thyroid Stimulating Hormone (TSH) level

    Time frame: Baseline, Through Week 20

  40. Percent change in serum TSH level

    Time frame: Baseline, Through Week 20

  41. Change in serum Thyroxine (T4) level

    Time frame: Baseline, Through Week 20

  42. Percent change in serum T4 level

    Time frame: Baseline, Through Week 20

  43. Change in serum total testosterone level

    Time frame: Baseline, Through Week 20

  44. Percent change in serum total testosterone level

    Time frame: Baseline, Through Week 20

  45. Change in serum free testosterone level

    Time frame: Baseline, Through Week 20

  46. Percent change in serum free testosterone level

    Time frame: Baseline, Through Week 20

  47. Change in serum 17-OHP level

    Time frame: Baseline, Through Week 20

  48. Percent change in serum 17-OHP level

    Time frame: Baseline, Through Week 20

  49. Change in serum estradiol level

    Time frame: Baseline, Through Week 20

  50. Percent change in serum estradiol level

    Time frame: Baseline, Through Week 20

  51. Change in serum DHEA-S level

    Time frame: Baseline, Through Week 20

  52. Percent change in serum DHEA-S level

    Time frame: Baseline, Through Week 20

  53. Change in serum androstenedione level

    Time frame: Baseline, Through Week 20

  54. Percent change in serum androstenedione level

    Time frame: Baseline, Through Week 20

  55. Change in serum Human Growth Hormone (HGH) level

    Time frame: Baseline, Through Week 20

  56. Percent change in serum HGH level

    Time frame: Baseline, Through Week 20

  57. Change in serum Insulin-like Growth Factor (IGF)-1 level

    Time frame: Baseline, Through Week 20

  58. Percent change in serum IGF-1 level

    Time frame: Baseline, Through Week 20

  59. Change in serum cortisol level

    Time frame: Baseline, Through Week 20

  60. Percent change in serum cortisol level

    Time frame: Baseline, Through Week 20

  61. Incidence of Anti-Drug Antibodies (ADA) to garetosmab

    Time frame: Through Week 32

  62. Titer of ADA to garetosmab

    Time frame: Through Week 32

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2025; primary completion for Jun 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 14, 2025
StartEst.
May 29, 2025
Primary completionEst.
Jun 8, 2026
CompletionEst.
Jun 8, 2026
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06970405
Responsible party
Sponsor
First posted
May 14, 2025
Start date
May 29, 2025 (estimated)
Primary completion
Jun 8, 2026 (estimated)
Completion
Jun 8, 2026 (estimated)
Last update
Sep 17, 2025

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Garetosmab

Start the discussion